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the first choice treatment and usually leads 
to an improvement in symptoms, functional 
status and survival. The 2006 American Col-
lege of cardiology (ACC)/American Heart 
Association (AHA) guidelines have made a 
Class I recommendation for AVR in symp-
tomatic patients with severe aortic stenosis 
[3]. AVR is also recommended, in certain cir-
cumstances, for patients with severe, asymp-
tomatic aortic valve stenosis and for patients 
with mild-to-moderate aortic valve stenosis 
that undergo coronary artery bypass grafts 
(CABG) as there is a significant possibility 
INTRODUCTION
Aortic stenosis is the most common valvu-
lar abnormality found in the United States 
[1] and its incidence is expected to increase 
due to the ageing patient population; as a 
matter of fact, the prevalence of moderate-
to-severe aortic stenosis increases from 2.5% 
at 75 years of age to 8.1% at 85 [2]. Aortic 
valve replacement (AVR) is the most com-
mon form of heart valve operation and ac-
counts for 60-70% of all valve surgery per-
formed on the elderly. In adults with severe, 
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ABSTRACT
Background: aortic valve replacement (AVR) the most common heart valve operation, accounts for a majority of all valve 
surgery performed in the elderly. The Perceval S (P) is a new aortic valve which is implanted without suturing, which 
causes a significant reduction in cross-clamping times (CCTs), and makes valve implantation easier and faster thanks to 
its collapsed profile. These features potentially allow the pool of operable patients to be expanded, even with minimally 
invasive surgery in isolated AVRs.
Aim: to predict costs and outcomes of AVR procedures associated with this new valve in 4 European countries (Italy, 
France, Germany, and UK), as compared to traditional (T) valve implants, from the cost perspective of the hospital.
Method: a probabilistic, patient-level simulation model was fully coded in WinBugs, permitting a seamless integration of 
parameter estimation and outcomes prediction, which was entirely based on the associated CCTs and on the surgical techni-
que (mini-invasive [MiS] vs. full sternotomy [FS]), through published correlations. Unit cost were retrieved from official 
and literature sources for all countries. Besides the incorporated probabilistic sensitivity analysis, a series of deterministic 
sensitivity analyses was performed.
Results: the model predicts the use of the Perceval S valve to be associated with less complications and with savings (valve 
cost excluded), mainly related to a reduction in surgery costs and ICU/hospital bed days. These savings ran ge from € 3,600 
(Italy) to £ 3,900 (UK) for PFS in isolated AVRs and from about € 6,000 (Italy) to £ 6,700 (UK) for PMiS in isolated AVRs, 
and for PFS in concomitants. Extensive sensitivity analyses confirm the robustness of such findings.
Conclusions: the results of the present analysis indicate that the hospital acquisition cost difference between the new sutu-
reless Perceval S  valve and traditional valves is offset by important savings in other cost items.
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cedural interventions (TAVI – Transcatheter 
Aortic Valve Implantation) have not been 
considered in this study, as their scope is de-
fined by surgical inoperability [17-19].
To this aim, a simulation model was built to 
estimate the effects of using different valves 
and surgical techniques on clinical outcomes, 
possible complications and related treatment 
costs.
METHODS AND MATERIALS
The probabilistic, patient-level simulation 
model was fully coded into WinBugs, an 
open-source software package for Bayesian 
statistical analysis.
The main surgical options available for pa-
tients that need AVR and are at medium-
to-high surgical risk can be defined by the 
type of prosthesis implanted (sutureless vs. 
sutured) and the surgical approach to the os-
tium (full sternotomy [FS] vs. mini-invasive 
[MiS] techniques). For patients that concom-
itantly undergo further procedures together 
with AVR, the model considers only the FS 
technique as being relevant. This reflects cur-
rent practice, as shown in the meta-analysis 
by Brown et al., in which only 44 out of over 
2,000 MiS patients underwent concomitant 
procedures [20].
On this basis, there are 5 strategies evalu-
ated in the present work; 3 for stand-alone 
procedures (the first for the traditional valve 
in full sternotomy, the second and third in-
volve Perceval S, both in full sternotomy and 
in MiS. Traditional valves implanted using 
MiS have not been considered as this surgical 
procedure has failed to achieve success and 
widespread application in real practice due to 
its high complexity), and 2 for concomitant 
procedures (traditional valve and Perceval S, 
only in FS).
Clinical data sources
Published, peer-reviewed literature was re-
lied on to feed the clinical side of our model. 
The correlations between CCTs and clinical 
outcomes were derived from an ad-hoc study, 
by Al-Sarraf et al., published in 2010 [11]. 
Surgical-technique specific outcome rates 
for patients with low CCT were elaborated 
(details in the next section) based on three 
matched case-control studies (Table I).
Sharony et al. published a case-control study 
[21] of FS vs. MiS in which groups were 
matched according to a large number of 
clinically relevant variables, thus minimiz-
ing the risk of potential confounders con-
tributing to or causing the observed differ-
ences. De Smet et al. [22] also compared the 
outcomes of aortic valve replacements that 
that the evolution of the disease may require 
an AVR within the expected life time of the 
patient.
AVR carries an operative (30 days) mortality 
risk of 3.0-4.0% which increases to 5.0-7.0% 
when performed in association with a CABG 
operation [1,3]. However, this expected mor-
tality rate may increase considerably where 
additional risk factors are present. Poor left 
ventricular systolic function increases the 
operative mortality risk to 8.0%-10% [4-7], 
and a recent study [8] highlighted an opera-
tive mortality rate of 6.5% in patients over 80 
years of age.
Due to the presence of a high-risk profile, a 
significantly large subset of patients that pres-
ent indications for valve surgery are deemed 
ineligible for conventional valve replacement 
because of these high-risk features or age [9]. 
One survey of 92 European heart centers 
found that 31.8 percent of patients with se-
vere, symptomatic, single valve disease did 
not undergo intervention, most frequently be-
cause of comorbidities [10]. Prolonged aortic 
cross-clamping times (CCTs) are an indepen-
dent risk factor for worse outcomes both in 
general cardiac surgery procedures [11,12] 
and in isolated AVR, as has been recently 
confirmed by the work of Ranucci et al. [13] 
on a sample of over 3,000 patients.
The Perceval S is a new aortic valve which is 
implanted without suturing, which causes a 
significant reduction in CCTs [14], and makes 
valve implantation easier and faster thanks to 
its collapsed profile. These features poten-
tially allow the pool of operable patients to 
be expanded, even with minimally invasive 
surgery (i.e. surgery performed with only a 
small incision, whether it be a right thoracot-
omy or a mini-sternotomy). It is known from 
the literature that this kind of approach is as-
sociated with less trauma and faster recovery, 
but also that it is associated with increased 
technical difficulty, when used with tradi-
tional valves, due to the need to operate in 
a very limited space. This has led to the very 
low uptake of this approach, which the avail-
ability of sutureless valves may overcome 
[15,16]. As is common for innovative tech-
nologies, the purchasing price of Perceval S 
is higher than traditional valves. This extra 
cost, however, may be partially or totally off-
set by savings on other components of care 
costs that a hospital treating a patient needing 
an AVR may accrue during (and after) his/
her hospital stay. Such costs may include op-
erating theatre costs and the management of 
complications. The aim of the present simu-
lation study is to comprehensively evaluate 
the cost of the main surgical alternatives for 
AVR in medium-to-high risk patients. Pro-
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reported on the implantation of both valve 
types and detailed surgical times for the su-
tureless valve that were very close to those 
observed for the corresponding technique in 
the Folliguet paper (37 and 34 minutes on 
average, respectively). These data were used 
for traditional valves implanted in isolated 
AVRs with a full sternotomy approach [24]. 
Finally, for traditional valves implanted in 
concomitant procedures, which Glauber has 
not reported on, data was taken from the 
surgical series published by McClure [25], 
which shows FS-isolated CCT distribution 
data that are broadly equivalent to those 
reported by Glauber for the same valve/ap-
proach/operation combination.
Table II summarizes these values and the cor-
responding calculated CCT zones distribu-
tions, which were again obtained by fitting 
gamma distributions to the observed data.








Sharony, 2003 [21] Traditional FS Case-control study 189 75 (7) 52 - 75 (24)
Traditional MiS 189 75 (6) 51 - 78 (22)
Bakir, 2006 [23] Traditional FS Retrospective, single 
centre, matched for 6 
criteria
274 71 (11) 56 - 70 (17)
Traditional MiS 232 69 (9) 51 - 62 (17)
De Smet, 2004 [22] Traditional FS Prospective and 
retrospective arms; 
single centre
91 68 (9) 58 5.6 (2.7) 79 (16)
Traditional MiS 100 70 (12) 48 6.0 (3) 79 (16)
Folliguet, 2012 [14] Perceval MiS Prospective, 
international, 
multicenter study
45 79 (5) 32 8.8# (5.3) 34 (10)
Perceval FS isolated 115 29^ (12)
Perceval FS concomitant 48 44 (13)




138 70 (12) 61 5.4§ 72 (27)
Traditional RT 138 70 (12) 58 5.6§ 87 (32)
McClure, 2010 [25] Traditional FS isolated Institutional 
prospective database




Table I. Main clinical studies considered – baseline patient parameters. Data are mean (SD), unless otherwise stated






< 60 min 60-90 min > 90 min
Isolated procedures
Traditional – FS 72 ± 27 35 41 24 Glauber, 2012 [24]
Perceval – FS 29 ± 12 98 2 0 Folliguet, 2012 [14]
Perceval – MiS 34 ± 10 99 1 0 Folliguet, 2012 [14]
Concomitant procedures
Traditional – FS 98 ± 31 10 34 56 McClure, 2010 [25]
Perceval – FS 44 ± 13 87 12 1 Folliguet, 2012 [14]
Table II. CCT distributions according to procedure, surgical approach and implanted valve
were performed either with MiS or FS in an 
institutional review of their surgical AVR 
series. Bakir et al. published a case-control 
MiS vs. FS study [23] conducted on over 500 
patients, matched on 6 relevant clinical cri-
teria; this study is deemed as of high-quality 
by published meta-analyses [16,20]. A criti-
cal step in the analysis was the choice of the 
data source for the attribution of CCT distri-
butions to the considered valve/surgical ap-
proach combinations, since no head-to-head 
randomized controlled trials were available. 
It was, thus, necessary to rely on the paper 
by Folliguet et al. for Perceval S-associat-
ed CCTs, as this is the only large clinical 
study published that has evaluated all three 
relevant alternatives (FS isolated, FS con-
comitant, and MiS) for the sutureless valve 
[14]. A literature search identified a series by 
the surgical team of Glauber et al. [24] that 
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The model relies on the assumptions that 
AVR outcomes depend on (Figure 1):
 - cross clamp time;
 - surgical technique (full sternotomy or 
minimal invasive surgery).
In order to develop the model we followed 
these steps: a) the identification of the in-
fluence of CCT and technique on AVR 
outcomes; b) an estimation of CCT times 
for each alternative; c) the prediction of 
technique-dependant and CCT + technique 
dependant outcomes; d) a run and an analy-
sis for the calibration and validation of the 
resulting model with published data; e) the 
construction of a cost structure that includes 
the surgery, the management of emerging ad-
verse events (AEs), the hospital stay and all 
related resource consumption, and finally f) 
the run and full result analysis.
Figure 1. Graphical representation of the model structure
PFS = Perceval full sternotomy; PMiS = Perceval mini-invasive surgery; TFS = traditional full sternotomy; TMiS = traditional mini-invasive surgery
Cross clamp time
To identify which outcomes are significantly 
influenced by the CCT, we relied on the cor-
relation study of CCTs and clinical outcomes 
published by Al-Sarraf in 2010 [11]. We were 
particularly interested in the cases of patients 
with a EuroScore of above 6 that confirmed 
a statistically significant association between 
at least one of the analyzed CCT categories 
(< 60 min, 61-90 min, and > 90 min) and the 
following clinical outcomes: mortality, post-
operative hospital length of stay (HLOS), 
ICU length of stay (ICULOS), renal compli-
cation rate, blood loss and bleeding rate, and 
ventilation time [11]. As can be seen in Table 
III, increasing CCT times are significantly as-
sociated with the worsening of several clini-
cally and economically relevant outcomes, 
such as mortality, overall and ICU lengths of 
stay and the occurrence of complications. For 
the simulation, OR estimates (vs. reference, 
i.e. CCTs < 60 min) reported by Al-Sarraf 
were transformed into relative risk (RR) dis-
tributions.
Surgical techniques (full sternotomy or 
minimal invasive surgery)
We identified outcomes that would depend 
on the surgical technique, but not on CCT, 
as those showing relevant differences in Sha-
rony [21] which, however, are not influenced 
by CCT (according to Al-Sarraf [11]), i.e. 
sepsis rate and the need for rehabilitation.
The rate of permanent pace-maker implant-
ing and stroke incidence, which were other 
initially considered outcomes, where later 
discarded as the literature reports controver-
sial data for them. For our model, outcomes 
that only depend on the surgical approach are 
shown in Table IV.
CCT + surgical technique
To identify which outcomes depend both on 
CCT and surgical technique, we relied on the 
meta-analyses of Brown [20] and Murtuza 
[16] that compared MiS vs. FS. CCT-depen-
Outcome
RRs vs. CCT < 60 min
Mean (95% CI)
CCT 60-90 min CCT > 90 min
In-hospital mortality 3.00 (1.39-6.22) 4.43 (1.87-9.97)
HLOS 1.20 (0.90-1.50) 2.30 (1.60-3.40)
ICU stay 1.30 (1.00-1.60) 3.00 (2.00-4.60)
Renal complications 1.54 (1.00-2.37) 2.05 (1.19-3.52)
Blood transfusion 1.05 (0.94-1.23) 1.60 (1.36-1.77)
Ventilation time 1.47 (0.81-2.44) 3.42 (1.92-5.65)
Table III. Modeled relationship between CCT strata and clinical outcomes, 
elaborated from Al-Sarraf et al. [11]
CCT = cross-clamping times, RRs = relative risks, HLOS = hospital length of stay, 
ICU = intensive care unit
Outcome FS MiS
Sepsis (%) 3.2 1.6
Discharge to rehab (%) 75.1 44.5
Conversion to FS (%) NA 3%
Table IV. Values of CCT-unrelated parameters, according to the surgical 
approach, from Sharony et al. [21]
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ternal validations consisted in comparing the 
model-predicted outcomes with the observed 
outcomes, using data from the studies on 
which the model is based. The external vali-
dations compared data observed in studies 
not involved in the modeling with model pre-
dictions obtained using only the information 
on CCTs and technique.
Sensitivity analyses
The probabilistic, patient-level simulation 
accounts for three types of uncertainty that 
are propagated throughout the model; the 
inter-individual variability among patients, 
uncertainty on parameter estimates (this is 
the reason for sampling from their full poste-
rior distribution), and the intrinsic unpredict-
ability of natural phenomena [26]. However, 
an extensive series of one-way sensitivity 
analyses has been incorporated to verify how 
influential the single modeled parameters are 
on the final cost estimate. These analyses are 
represented as tornado diagrams, in which 
the parameters are ranked in descending or-
der of influence.
Definition of costs
The modeled costs structure, related to hos-
pitalization for an AVR, is simplified in Fig-
ure 2 and implemented for the cost analysis 
Figure 2. Graphical representation of the costs structure
dant outcomes (according to Al-Sarraf [11]). 
Those that were better with MiS despite in-
creased CCT times were selected.
For these outcomes, the model estimated 
technique-specific rates for CCTs < 60 min 
(R
lowCCT
 – Table V) by decomposing overall 
observed rates (R
obs
 - mean ± SD) using the 
RRs of Table III and the trial-reported distri-
butions of CCTs for that rate, according to the 
general formula:
Robs = RlowCCT • %lowCCT + RlowCCT • %mediumCCT 
• RRmediumCCT + RlowCCT • %highCCT • RRhighCCT
where %
XCCT
 is the proportion of CCT times 
in the X category among the patient popula-
tion contributing to the R
obs
, as estimated by 
WinBugs on the basis of the reported mean ± 
SD, assuming that these times follow a gam-
ma distribution. An example using means 
only would be as follows: supposing it is 
known that a general population is made up 
of two groups, of which the relative numer-
ousness (say, A = 50, B = 50) and the relative 
risk of an event between them are known (say 
1:2). The overall event rate was 30% and we 
would like to calculate the rate in the low risk 
group. By solving the equation Overall Rate 
(30%) = %A • RiskA + %B • RiskB = 0.5 • 
RiskA + 0.5 • RiskA • 2 = 1.5 RiskA, we ob-
tain RiskA = 20% and RiskB = 40%.
Given the availability of the distributions for 





for all CCT-depending outcomes, 
the model is able to perform a patient-level 
simulation by sampling a value for each pa-
rameter and predicting the individual out-
come. For technique-only dependant out-
comes, the simulation is simply based on the 
sampling of an individual value from the rel-
ative distribution for the pertinent technique.
Validation
In order to evaluate the predictive perfor-
mance of the model, a series of internal and 
external validations were performed. The in-
Outcome FS MiS Source
HLOS (days) 10.5 ± 12.4 8.4 ± 9.1 Sharony, 2003 [21]
ICULOS (days) 1.6 ± 2.0 1.2 ± 1.4 De Smet, 2004 [22]
Blood loss in OP (ml) 266 ± 66 280 ± 68 De Smet, 2004 [22]
Blood loss in ICU (ml) 359 ± 83 283 ± 69 De Smet, 2004 [22]
Ventilator days 1.0 ± 3.7 1.1 ± 0.6 Bakir, 2006 [23]
Incident dialysis (%) 1.21 ± 0.77 1.95 ± 1.03 Sharony, 2003 [21]
Re-operation for 
bleed (%)
4.39 ± 1.57 2.92 ± 1.27 Sharony, 2003 [21]
Table V. Estimated values (mean ± SD) for low CCT groups, according to 
surgical approach
HLOS = hospital length of stay; ICULOS = ICU length of stay
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of the four European countries considered; 
Italy, Germany, France and the UK. Only 
the direct health care costs accrued for valve 
replacement and for the managing of com-
plications were considered. All health care 
resources used during index hospitalization 
were included in hospital costs. All past costs 
were updated to 2011 (2012 only for Italian 
costs) values using official inflation indices 
[27,28], while the most recent valid value has 
been used for tariffs.
Surgery cost
An approximate cost of the procedure is 
calculated based on the cost of the operat-
ing theatre, including materials cost, and the 
value of the labor of the health care personnel 
involved. It was decided to omit valve costs 
and focus on the difference that emerges from 
the consumption of other resources.
For this purpose, the following assumptions 
were made:
 - The theatre was considered to be em-
ployed for a mean procedure time, com-
mon to all the procedure types (on aver-
age 130 min [16]), plus the CCT specific 
for each procedure, plus half an hour for 
room preparation/asepsis [29].
 - Several health care professionals are in-
volved during a procedure. The costs of 2 
surgeons, 1 anaesthesiologist, one assis-
tant anaesthesiologist, 1 instrumentalist, 
1 perfusionist, one nurse and one health 
operator (for asepsis only) were consid-
ered in our analysis.
 - The transfusion of a single red blood cell 
unit was considered for blood losses be-
tween 500 ml and one liter, above which 
the transfusion of two units was taken 
into account.
 - The impact of ventilation time was re-
lated to the development of ventilator-as-
sociated pneumonia, according to the cu-
mulative incidence reported by VanHems 
et al. [30].
According to an analysis conducted on 
seven Italian operating rooms by an associa-
tion of hospital medical directors, one min-
ute of operating theatre use costs around € 
22 (2008 value) [31]. The same value was 
modeled for the French and German analy-
ses because of a lack of specific information, 
whereas a mean cost/minute of £ 20 for the 
year 2009 was estimated in a UK project 
carried out by the NHS institute for innova-
tion and improvement [32] and used in our 
study.
The unit cost for health personnel labor was 
estimated according to real hospital-borne 
costs for Italy, France, Germany and the UK 
[33-36].
An official blood bag tariff was taken as 
a proxy of the real cost for the collection, 
transportation and storage of patient blood 
[37-40]. The hospital cost of one autologous 
RBC unit (collection and storage) was con-
sidered for the UK analysis [41].
Unit costs, expressed as current prices, are 
detailed in Table VI.
Hospital stay cost
The total cost of a hospital stay was made up 
of the cost of the ICU in which the patient 
spends the days immediately after the surgi-
cal procedure plus the cost of the standard 
ward which hosts the patient after the critical 
post-operative phase has been completed.
For Italy, the cost per ward day was estimated 
according to a retrospective analysis of re-
sources consumed by 87 patients hospitalized 
for TAVI (trans-catheter aortic valve implanta-
tion) (Ospedale Sant’Orsola di Bologna) [44].
It was decided to use an analysis conducted 
by the WHO for the other countries [45]. An 
ICU day cost was obtained from observational 
studies that are specific for each country, after 
cost items already included in the model were 
excluded [46-49]. Unit costs, expressed as 
current prices, are summarized in Table VII.
Complications cost
The events considered in the present analysis 
as linked to the surgical procedure and com-
plicating the normal postoperative course 
are sepsis, renal failure, ventilator-associ-
ated pneumonia and bleeding that leads to 
re-operation. The possible prolongation of 
a hospital stay that derives from the onset 
of complications is already reflected in the 
overall mean LOS statistics. In order to avoid 
double counting, complications cost has been 
limited to the adjunctive diagnostic tests/pro-
cedures, drugs and extra materials needed for 
their management. Rehabilitation was also 
included in the complications cost section.
For all the countries, except Germany, the to-
tal adjunctive resource consumption due to the 
Parameters Italy (€) Source France (€) Source Germany (€) Source UK (£) Source
Minute of OR 23.50 ANMDO [31] 23.50 ANMDO 
[31]
23.50 ANMDO [31] 21.28 NHS, 2009 [32]
Health personnel costs (per minute)
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Table VI. Surgery section, unit costs
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Table VI. Surgery section, unit costs
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Table VII. Hospital stay costs
management of sepsis, with the exclusion of 
increased length of stay, was estimated as the 
difference in the mean cost per hospital day 
of a patient with sepsis and a patient without, 
multiplied by the average number of hospital 
days needed to manage the event [46,50,51].
In Germany, a bottom-up approach study into 
the cost per severe sepsis episode has been 
published [52]. According to the type of pa-
tients simulated in the present analysis, we 
adopted the value estimated for the surgical 
patients subgroup of the entire cohort en-
rolled in the study.
The cost of hospital haemodialysis treatment 
was included as a complication cost for pa-
tients that developed renal failure. The real 
costs of two kinds of procedure (continuous 
and intermittent hemodialysis) were used for 
Italy [53]. Hospital dialysis session tariffs 
were used as a proxy for hospital-borne cost 
for the other countries, and a frequency of 3 
sessions per week was assumed [40,43,54].
USA data were used to estimate the cost of 
hospital-acquired pneumonia for Italy and 
the UK, because of a lack of detailed data 
pertaining to these countries that would per-
mit an episode cost excluding the cost an 
increased LOS to be calculated [55]. VAP 
cost in France and the UK was estimated via 
country-specific cost analyses [56,57].
The cost of re-operation because of bleeding 
was assumed to be equal to mean procedure 
time, with CCT and asepsis times excluded 
(160 minutes), multiplied by the cost per min-
ute of operating health personnel and room use.
Finally, the cost for rehabilitation was ap-
proximated using current tariffs for reha-
Parameters Italy (€) Source France (€) Source Germany (€) Source UK (£) Source








Dialysis H day 311.31 Vitale, 2003 
[53]
















261.41 TUC, 2011 
[58]






Table VIII. Complications cost
VAP = ventilation associated pneumonia
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ing the first 20,000 run-in iterations, are 
shown in Table VIII and in Table IX. 
For isolated procedures, the model predicts 
that the total costs (net of valve) are consid-
erably lower on average when a Perceval S 
valve is implanted using mini-invasive tech-
niques than when a traditional, sutured valve 
is implanted using the full sternotomy ap-
proach. The comparison of the cost figures of 
the three considered valve/surgical approach 
combinations highlights that a conspicuous 
part of the potential saving is related to the 
overcoming of the need for suturing (com-
parison between TFS and PFS), and that an-
other, also significant, amount can be saved 
by switching to the less invasive surgical 
approaches. The amount and relative im-
portance of the attainable savings depend on 
the local setting, although the absolute esti-
mated figures are quite consistent across the 
V/SA Surgery Ward Rehabilitation ICU Complications Total Delta*
Italy (€) TFS 7,201 (871.4) 4,937 (1,443) 3,925 (164.4) 3,365 (4,271) 352.8 (145) 19,780 (5,512) -
PFS 5,855 (384.2) 3,723 (140.8) 3,925 (164.4) 2,362 (2,086) 280.3 (80.33) 16,150 (2,190) 3,602 (66.42)
PMiS 5,891 (297.7) 3,298 (39.94) 2,326 (190.4) 2,057 (1,561) 238.8 (79.13) 13,810 (1,631) 5,970 (63.53)
France 
(€)
TFS 8,589 (1,057) 5,331 (1,559) 3,930 (164.7) 4,029 (5,112) 426.4 (137.5) 22,310 (6,455) -
PFS 6,956 (466.1) 4,021 (152.1) 3,930 (164.7) 2,828 (2,497) 368.9 (101.8) 18,100 (2,611) 4,164 (71.54)
PMiS 7,002 (361.2) 3,561 (43.13) 2,329 (190.7) 2,462 (1,869) 288.4 (92.56) 15,640 (1,942) 6,663 (74.45)
Germany 
(€)
TFS 6,932 (835.5) 5,377 (1,572) 4,359 (182.6) 3,463 (4,395) 259.7 (79.56) 20,390 (5,637) -
PFS 5,641 (368.4) 4,056 (153.4) 4,359 (182.6) 2,431 (2,147) 229.1 (62.91) 16,720 (2,611) 3,641 (67.15)
PMiS 5,676 (285.4) 3,592 (43.5) 2,583 (211.4) 2,116 (1,607) 166.7 (57.24) 14,130 (1,663) 6,257 (65.05)
UK (£) TFS 6,813 (828.9) 4,456 (1,303) 4,398 (184.3) 5,167 (6,557) 483.9 (142.1) 21,320 (7,523) -
PFS 5,533 (365.5) 3,361 (127.1) 4,398 (184.3) 3,627 (3,203) 441.1 (124.8) 17,360 (2,611) 3,915 (74.71)
PMiS 5,568 (283.2) 2,976 (36.05) 2,607 (213.4) 3,158 (2,397) 299 (106.4) 14,610 (2,447) 6,711 (87.17)
Table IX. Simulation results for isolated AVR procedures (Traditional FS vs Perceval MiS)
* Data presented as mean  (SEM) vs. TFS
FS = full sternotomy; MiS = mini-invasive surgery; P = Perceval; T = traditional; V/SA = valve/surgical approach
bilitation services in the 4 countries. Given 
the considered time horizon and guideline 
recommendations for post-cardiac surgery 
rehabilitation, this service was set at 20 days. 
Unit costs expressed as current prices are 
presented in Table VIII.
RESULTS
The internal validation series indicates that 
the model is satisfactorily capable of replicat-
ing observed data (Figure 3). 
The external validation shows acceptable 
model prediction capabilities. Even when 
predicted values are not particularly similar 
to the central estimate (mean or median, de-
pending on the outcome), the observed data 
are always well within the predicted 95% CI 
(Figure 4).
The results of the simulations, obtained with 
20,000 iterations of the model after discard-
Figure 3. Results of internal validations on rates (A) and LOSs (B)
Figure 4. Results of external validation on rates (A), ICU lengths of stay and transfused blood units (B)
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ing the first 20,000 run-in iterations, are 
shown in Table VIII and in Table IX. 
For isolated procedures, the model predicts 
that the total costs (net of valve) are consid-
erably lower on average when a Perceval S 
valve is implanted using mini-invasive tech-
niques than when a traditional, sutured valve 
is implanted using the full sternotomy ap-
proach. The comparison of the cost figures of 
the three considered valve/surgical approach 
combinations highlights that a conspicuous 
part of the potential saving is related to the 
overcoming of the need for suturing (com-
parison between TFS and PFS), and that an-
other, also significant, amount can be saved 
by switching to the less invasive surgical 
approaches. The amount and relative im-
portance of the attainable savings depend on 
the local setting, although the absolute esti-
mated figures are quite consistent across the 
V/SA Surgery Ward Rehabilitation ICU Complications Total Delta*
Italy (€) TFS 7,201 (871.4) 4,937 (1,443) 3,925 (164.4) 3,365 (4,271) 352.8 (145) 19,780 (5,512) -
PFS 5,855 (384.2) 3,723 (140.8) 3,925 (164.4) 2,362 (2,086) 280.3 (80.33) 16,150 (2,190) 3,602 (66.42)
PMiS 5,891 (297.7) 3,298 (39.94) 2,326 (190.4) 2,057 (1,561) 238.8 (79.13) 13,810 (1,631) 5,970 (63.53)
France 
(€)
TFS 8,589 (1,057) 5,331 (1,559) 3,930 (164.7) 4,029 (5,112) 426.4 (137.5) 22,310 (6,455) -
PFS 6,956 (466.1) 4,021 (152.1) 3,930 (164.7) 2,828 (2,497) 368.9 (101.8) 18,100 (2,611) 4,164 (71.54)
PMiS 7,002 (361.2) 3,561 (43.13) 2,329 (190.7) 2,462 (1,869) 288.4 (92.56) 15,640 (1,942) 6,663 (74.45)
Germany 
(€)
TFS 6,932 (835.5) 5,377 (1,572) 4,359 (182.6) 3,463 (4,395) 259.7 (79.56) 20,390 (5,637) -
PFS 5,641 (368.4) 4,056 (153.4) 4,359 (182.6) 2,431 (2,147) 229.1 (62.91) 16,720 (2,611) 3,641 (67.15)
PMiS 5,676 (285.4) 3,592 (43.5) 2,583 (211.4) 2,116 (1,607) 166.7 (57.24) 14,130 (1,663) 6,257 (65.05)
UK (£) TFS 6,813 (828.9) 4,456 (1,303) 4,398 (184.3) 5,167 (6,557) 483.9 (142.1) 21,320 (7,523) -
PFS 5,533 (365.5) 3,361 (127.1) 4,398 (184.3) 3,627 (3,203) 441.1 (124.8) 17,360 (2,611) 3,915 (74.71)
PMiS 5,568 (283.2) 2,976 (36.05) 2,607 (213.4) 3,158 (2,397) 299 (106.4) 14,610 (2,447) 6,711 (87.17)
Table IX. Simulation results for isolated AVR procedures (Traditional FS vs Perceval MiS)
* Data presented as mean  (SEM) vs. TFS
FS = full sternotomy; MiS = mini-invasive surgery; P = Perceval; T = traditional; V/SA = valve/surgical approach
bilitation services in the 4 countries. Given 
the considered time horizon and guideline 
recommendations for post-cardiac surgery 
rehabilitation, this service was set at 20 days. 
Unit costs expressed as current prices are 
presented in Table VIII.
RESULTS
The internal validation series indicates that 
the model is satisfactorily capable of replicat-
ing observed data (Figure 3). 
The external validation shows acceptable 
model prediction capabilities. Even when 
predicted values are not particularly similar 
to the central estimate (mean or median, de-
pending on the outcome), the observed data 
are always well within the predicted 95% CI 
(Figure 4).
The results of the simulations, obtained with 
20,000 iterations of the model after discard-
Figure 3. Results of internal validations on rates (A) and LOSs (B)
Figure 4. Results of external validation on rates (A), ICU lengths of stay and transfused blood units (B)
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countries considered and range from almost 
€ 6,000 in Italy to slightly over £ 6,700 in 
the UK for the TFS vs. PMiS comparison, 
and from roughly € 3,600 to about £ 3,900 
for the PFS vs. PMiS comparison. The con-
tribution of the different cost items to the 
overall saving is also variable across the 
countries, although the main cost difference 
drivers are ward stay, ICU stay, surgical pro-
cedure and rehabilitation, each contributing 
about a quarter in all analyzed settings. The 
relatively small standard error of the mean 
(SEM) difference indicates that these results 
are robust, as assessed by the probabilistic 
sensitivity analysis incorporated within the 
simulation.
For concomitant procedures, the overall pre-
dicted saving is similar to that estimated for 
PMiS vs. TFS in isolated procedures, al-
though the contribution of the single cost 
items is quite different. The costs for reha-
bilitation do not contribute to the estimated 
differences, and consequently the effect of 
fewer bed days and shorter surgical proce-
dures gain more relative importance. The un-
certainty reflected in the probabilistic struc-
ture of the model can be seen in the very 
small SEM difference for concomitant proce-
dures, as was the case for the isolated proce-
dures.
The results of the deterministic sensitivity 
analyses for Italy are depicted in Figures 5-8. 
Surgery Ward ICU Rehabilitation Complications Total Delta*
Italy (€) T 8,011 (1,018) 6,072 (1,535) 4,365 (5,468) 3,925 (164.4) 430.5 (172.3) 22,800 (6,653) 6,063 (58.48)
P 6,294 (423.5) 3,816 (324.9) 2,420 (2,206) 3,925 (164.4) 284.8 (83.24) 16,740 (2,408)
France (€) T 9,572 (1,235) 6,557 (1,658) 5,226 (6,546) 3,930 (164.7) 492.6 (154.4) 25,780 (7,823) 6,968 (68.27)
P 7,490 (513.7) 4,121 (350.8) 2,897 (2,641) 3,930 (164.7) 371.7 (102.5) 18,810 (2,860)
Germany (€) T 7,709 (976.4) 6,614 (1,672) 4,492 (5,628) 4,359 (182.6) 295.4 (87.42) 23,470 (7,823) 6,169 (59.74)
P 6,063 (406) 4,156 (353.9) 2,491 (2,270) 4,359 (182.6) 230.5 (63.11) 17,300 (2,860)
UK (£) T 7,584 (968.7) 5,481 (1,386) 6,703 (8,397) 4,398 (184.3) 535.5 (151.3) 24,700 (7,823) 6,748 (77.57)
P 5,951 (402.9) 3,444 (293.3) 3,716 (3,388) 4,398 (184.3) 442.9 (124.8) 17,950 (2,860)
Table X. Simulation results for concomitant AVR procedures
* Data presented as mean (SEM)
P = Perceval; T = traditional
One-way sensitivity analyses (Figure 5 and 
Figure 6) indicate that the total cost per Per-
ceval case is most sensitive to the unit costs 
of the bed days in the ward and ICU, and to 
the cost of rehabilitation. The average cost 
per implantation of traditional valves is most 
sensitive to the aortic cross-clamp time. The 
mean cost of the alternative valve/approach 
combinations do not overlap for either iso-
lated or concomitant procedures within the 
+/- 20% variation in any parameter.
Single parameter two-way sensitivity analy-
ses (Figure 7 and Figure 8) were performed 
by concurrently worsening the estimate for 
Perceval by 20% and improving the same es-
timate for traditional by 20% (worst case), 
and vice versa (best case).
The estimated cost difference between TFS 
and PMiS in isolated AVRs ranges from 
about € 3,710 (worst case – surgery cost per 
minute; +20% for P while – 20% for T) to 
€ 8,230 (best case, opposite). In concomitant 
procedures, the estimated cost difference be-
tween T and P ranges from € 3,570, in the 
hypothesis that CCTs of P are 20% higher 
than assumed and those of T 20% lower, and 
€ 9,300 in the opposite case.
DISCUSSION
Health economic evaluations aim at provid-
ing a rational trade-off between rising sani-Figure 5. Tornado diagrams: one-way sensitivity analyses showing the influence of single parameters on the results for isolated AVRs
Figure 6. One-way sensitivity analysis showing the influence of single parameters on the results for concomitant procedures
Figure 7. Two-way sensitivity analysis on the cost difference between TFS and 
PMiS. See text for explanation
Figure 8. Two-way sensitivity analysis on the cost difference between traditional 
and Perceval in concomitant procedures. See text for explanation
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One-way sensitivity analyses (Figure 5 and 
Figure 6) indicate that the total cost per Per-
ceval case is most sensitive to the unit costs 
of the bed days in the ward and ICU, and to 
the cost of rehabilitation. The average cost 
per implantation of traditional valves is most 
sensitive to the aortic cross-clamp time. The 
mean cost of the alternative valve/approach 
combinations do not overlap for either iso-
lated or concomitant procedures within the 
+/- 20% variation in any parameter.
Single parameter two-way sensitivity analy-
ses (Figure 7 and Figure 8) were performed 
by concurrently worsening the estimate for 
Perceval by 20% and improving the same es-
timate for traditional by 20% (worst case), 
and vice versa (best case).
The estimated cost difference between TFS 
and PMiS in isolated AVRs ranges from 
about € 3,710 (worst case – surgery cost per 
minute; +20% for P while – 20% for T) to 
€ 8,230 (best case, opposite). In concomitant 
procedures, the estimated cost difference be-
tween T and P ranges from € 3,570, in the 
hypothesis that CCTs of P are 20% higher 
than assumed and those of T 20% lower, and 
€ 9,300 in the opposite case.
DISCUSSION
Health economic evaluations aim at provid-
ing a rational trade-off between rising sani-Figure 5. Tornado diagrams: one-way sensitivity analyses showing the influence of single parameters on the results for isolated AVRs
Figure 6. One-way sensitivity analysis showing the influence of single parameters on the results for concomitant procedures
Figure 7. Two-way sensitivity analysis on the cost difference between TFS and 
PMiS. See text for explanation
Figure 8. Two-way sensitivity analysis on the cost difference between traditional 
and Perceval in concomitant procedures. See text for explanation
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(prolonged mechanical ventilation, ICU and 
hospital stay).
The present simulation study confirms that 
the expected reduction of morbidity rate ob-
tained by reducing the CCT with sutureless 
valve implantation results in a considerable 
cost-saving, mainly due to a shortening of 
ICU and hospital stay.
The major limitation of the present study is 
the relatively small number of studies pub-
lished in this area. Additionally, there are no 
randomized controlled studies to provide a 
high level of evidence. Due to these limita-
tions, it is difficult to structure a model that 
takes into account the specific cost-savings 
related to a specific reduction in each mor-
bidity event (stroke, acute renal failure, low 
cardiac output, etc.). However, both the ICU 
and the hospital stay may be considered as 
surrogates for “any kind of morbid events” 
which invariably prolong both these vari-
ables.
Modeling in health economics is intended 
to provide an abstraction process through a 
simplified simulation of the alternative inter-
ventions and their consequences, including 
multiple therapeutic decisions and relevant 
event probabilities, coupled with the asso-
ciated resource consumption. The results of 
a model cannot, by any means, be regarded 
as an absolute effectiveness claim, but in 
their interpretation it should always be kept 
in mind that the objective of the analysis is 
the “comparative assessment” of cost and 
outcomes of two or more healthcare tech-
nologies evaluated “under the same set of 
assumptions” (i.e. the model). The results 
of our validation series confirm that this is 
also the case for the present model; compari-
sons between strategies systematically show 
the right direction and a close magnitude, 
although absolute estimates are not always 
very accurate. This is easily explained if one 
considers how other factors influence con-
sidered outcomes. Mortality is surely deter-
mined by individual features that are not in-
cluded in the model, while lengths of stay are 
clearly also determined by organizational as-
pects, and not only by patient outcomes. But, 
as is inherent in the definition of independent 
variables, the effects of CCT and technique 
act on top of these baseline features, and this 
is reflected in our results.
Another limitation that is worth mentioning 
concerns the input data on the cross-clamp 
times that have been selected. Although great 
effort has been put into retrieving literature 
data that permit CCT distributions to be as-
signed to the alternatives based on clear and 
fair criteria, the absence of a surgical series 
that reports on all considered technique/
tary needs and the limited health care budget 
through the principle of efficient allocation of 
resources, and at valuing medical and tech-
nological innovation in terms of willingness 
to pay.
The assessment of the economics of an in-
tervention, through pragmatic trials or obser-
vational studies, is a complex and expensive 
process which can take years or which, in 
some cases, is simply infeasible. However, 
health economics decisions have to be made, 
and “Such considerations (...) have led to the 
view held by some health economists that 
modeling in economic evaluation is an un-
avoidable fact of life” [63].
The present study proposes a cost analysis 
model based on the hypothesis that a reduc-
tion in CCT during the surgical replacement 
of a stenotic aortic valve may reduce the to-
tal cost of the procedure. This hypothesis is 
justified by the recent introduction of aortic 
valve bioprostheses (sutureless) that can be 
implanted in a shorter period of time, there-
fore decreasing the CCT.
The main result of this simulation model is 
that the use of sutureless aortic valve bio-
prostheses results in an overall decrease of 
costs in the range of 6,000 – 7,000 Euros 
for both isolated and combined operations. 
Various items determine this cost saving, the 
most relevant being a reduction in surgery, 
ICU stay and ward stay costs.
Previous studies have highlighted that CCT 
is an independent risk factor for a number of 
postoperative complications in cardiac sur-
gery, including low cardiac output and acute 
renal failure [11]. This leads to a direct and 
independent association of CCT with me-
chanical ventilation time and ICU and hos-
pital stay duration [11]. It was observed that 
CCT has a direct impact on operative mor-
tality for specific categories of patients; Fla-
meng et al. [64] were able to demonstrate the 
existence of 1.8% increase in relative mortal-
ity risk per minute increase in CCT.
In the specific setting of surgical stenotic 
aortic valve replacement, Ranucci et al. [13] 
demonstrated that CCT is an independent 
predictor of a composite morbidity index 
(including low cardiac output, stroke, acute 
renal failure and mortality), with a relative 
increase in morbidity of 1.6% per minute 
CCT increase. Low cardiac output, stroke 
and acute renal failure are among the most 
common complications in cardiac surgery 
and consume considerable amounts of time 
and resources. The costs involved in this 
kind of complication are both direct (due to 
the use of specific devices, such as the intra-
aortic balloon pump, ventricular assist devic-
es, hemofiltration/dialysis, etc.) and indirect 
171Farmeconomia. Health economics and therapeutic pathways 2012; 13(4) © SEEd All rights reserved
L. Pradelli, O. Zaniolo
analysis indicate that the hospital acquisition 
cost difference between the new sutureless 
Perceval S valve and traditional valves is off-
set by important savings in other cost items. 
This cost saving is found in reduced CCTs 
and/or in the increased suitability of the valve 
in minimally invasive techniques which leads 
to shorter stays in the ICU and in the hospital 
as a whole, due a lower occurrence of com-
plications.
valve combinations performed by the same 
team may limit the reliability of these data 
to some extent. However, sensitivity analyses 
show that the conclusions are only affected to 
a limited extent by this uncertainty.
CONCLUSIONS
Despite some limitations that are inherent to 
simulation studies, the results of the present 
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